ARID1A deletion in ovarian cancer can transcriptionally activate MRP2 protein expression after chromatin remodeling, leading to multidrug resistance to carboplatin and paclitaxel in ovarian cancer (62). This evidence concerns the gene ARID1A and ovarian cancer.